Navigation Links
One in 4 children with leukemia not taking maintenance medication, study shows
Date:6/2/2014

(WASHINGTON, June 2, 2014) An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published online today in Blood, the Journal of the American Society of Hematology. The study also reports that maintenance medication adherence was lower in African American and Asian children in remission from ALL than in non-Hispanic white children, with 46 percent of African Americans and 28 percent of Asians not taking enough to prevent relapse, compared with 14 percent of non-Hispanic whites.

Acute lymphocytic leukemia (ALL), a cancer of the white blood cells, is the most common form of childhood cancer. While more than 95 percent of children with ALL enter remission within a month of receiving initial cancer therapy, one in five will relapse. In order to remain cancer-free, children in remission from ALL must take a form of oral chemotherapy every day for two years (called 6-mercaptopurine, or 6MP) that protects the body against disease reemergence.

Despite the proven benefits of 6MP, previous studies have suggested that children with ALL have difficulty taking the drug consistently. Other studies have reported that pediatric ALL survival rates vary greatly among racial groups. These two insights have prompted investigators to begin studying race-specific patterns in 6MP adherence in children with ALL.

"While we don't yet know why children of different races have significantly different survival rates for ALL, we know that their adherence to their maintenance medication is a critical factor in their survival," said senior study author Smita Bhatia, MD, MPH, of City of Hope in Duarte, California. "With this in mind, we sought to explore the potential linkages that may exist between several key race-specific sociodemographics of these children and their adherence to 6MP."

Dr. Bhatia and a team of investigators began their research studying differences in 6MP adherence among different racial groups of children in remission from ALL in 2012, reporting that Hispanic children did not follow their prescribed 6MP maintenance regimen as consistently as non-Hispanic whites. To examine 6MP adherence in African American, Asian, and non-Hispanic white children in remission from ALL, the research team enrolled 298 patients from 77 institutions in a study that tracked 6MP drug levels in the bloodstream, responses from a questionnaire administered to their families, and, perhaps most importantly, an electronic method for monitoring maintenance. Each patient enrolled in the study, who was prescribed 6MP, was provided with a pill bottle equipped with a microprocessor chip in the cap that recorded each date and time the bottle was opened for a period of six months.

Of all three groups, the African American children took their 6MP the least often, with 46 percent of them taking 90 percent or less of their medication, the threshold for nonadherence at which risk of relapse became statistically significant. While the Asian children in the study group took their medication more consistently, 28 percent of them did not take at least 90 percent of their medication. Non-Hispanic white children were more adherent to their maintenance therapy regimen than any other group; however, 14 percent still did not take enough 6MP to meet researchers' criterion for drug adherence. Taken together, approximately 25 percent of the children enrolled in the study did not take their 6MP at least 90 percent of the time, tripling their relapse risk.

In order to better understand the sociodemographic factors that may have influenced medication nonadherence among the children, researchers asked their families to complete questionnaires to provide more information about the family's race, income, structure, and paternal education level. Questionnaire responses revealed that the African American children came largely from low-income, single-family households with lower parental education level (less than college degree/vocational training). Conversely, Asian children in general came from high-income, nuclear families with well-educated parents (college degree/vocational training or postgraduate degree). Despite representing both sociodemographic extremes, neither group adhered to their medication as consistently as the non-Hispanic white children, who reported more moderate income, relatively nuclear family structure, and average paternal education when compared to the other groups, in part because race-specific sociodemographic characteristics played significant roles in adherence to 6MP.

Researchers observed that 6MP adherence rates were significantly higher among Asian and African American children who came from households in which their mother acted as their full-time caregiver and medication supervisor. In addition, according to research data, African American children whose mothers had a relatively low level of education as well as those children who lived in single-parent, multiple-children households were less adherent to their medication. Researchers also noted that Asian children were more vulnerable to medication nonadherence if they came from low-income households and that Non-Hispanic whites did not take their medication as consistently if their fathers had a low education level.

Regardless of race, families reported that the most common reason for children not taking their 6MP medication was forgetfulness.

"Our data demonstrate that one in four children in remission from ALL does not take the medicine needed to remain cancer free, and in an overwhelming majority, the primary reason why is that they forget to take their pills each day," said Dr. Bhatia. "These results are the basis for further studies that will examine how physicians can successfully intervene, using technology, for example, to ensure that children do not experience an increased risk of relapse because they did not take their oral chemotherapy."


'/>"/>

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. In children born with severe heart defect, surgical management has little effect on neuro outcomes
3. Children Born to Obese Moms May Face Higher Autism Risk: Study
4. Supporting LGB children may influence their long-term health, BU study finds
5. Out-of-hand tree nut consumption associated with better diet quality in children and adults
6. BASPCAN - UK-wide increase in number of children
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. U.S. Children Exposed to Hours of Background TV Daily
9. Leaders in childrens health to gather in Boston
10. Dietary changes help some children with ADHD
11. Bullied Children at Greater Risk for Self-Harm, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: